- Home
- XBIT vs ACHV Comparison
XBIT vs ACHV Comparison
Compare XBIT & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIT
- ACHV
- Stock Information
- Founded
- XBIT 2005
- ACHV N/A
- Country
- XBIT United States
- ACHV Canada
- Employees
- XBIT N/A
- ACHV N/A
- Industry
- XBIT Pharmaceuticals and Biotechnology
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- XBIT Health Care
- ACHV Health Care
- Exchange
- XBIT Nasdaq
- ACHV Nasdaq
- Market Cap
- XBIT 89.6M
- ACHV 72.5M
- IPO Year
- XBIT 2015
- ACHV N/A
- Fundamental
- Price
- XBIT $2.50
- ACHV $3.35
- Analyst Decision
- XBIT
- ACHV Strong Buy
- Analyst Count
- XBIT 0
- ACHV 3
- Target Price
- XBIT N/A
- ACHV $14.33
- AVG Volume (30 Days)
- XBIT 52.8K
- ACHV 325.9K
- Earning Date
- XBIT 08-11-2025
- ACHV 08-12-2025
- Dividend Yield
- XBIT N/A
- ACHV N/A
- EPS Growth
- XBIT N/A
- ACHV N/A
- EPS
- XBIT N/A
- ACHV N/A
- Revenue
- XBIT N/A
- ACHV N/A
- Revenue This Year
- XBIT N/A
- ACHV N/A
- Revenue Next Year
- XBIT N/A
- ACHV N/A
- P/E Ratio
- XBIT N/A
- ACHV N/A
- Revenue Growth
- XBIT N/A
- ACHV N/A
- 52 Week Low
- XBIT $2.50
- ACHV $1.84
- 52 Week High
- XBIT $8.32
- ACHV $5.31
- Technical
- Relative Strength Index (RSI)
- XBIT 33.01
- ACHV 52.46
- Support Level
- XBIT $2.57
- ACHV $3.44
- Resistance Level
- XBIT $2.78
- ACHV $3.91
- Average True Range (ATR)
- XBIT 0.14
- ACHV 0.30
- MACD
- XBIT -0.03
- ACHV -0.09
- Stochastic Oscillator
- XBIT 0.00
- ACHV 28.03
About XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.